Brexpiprazole as a new approach of treatment in somatization disorder
Introduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g. palpitations, dizziness, diarrhoea, limb weakness, pain, and pseudo neurological symptoms) accompanied by one or more thoughts, feelings, and/or behaviours related to the somatic sympt...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Series: | Emerging Trends in Drugs, Addictions, and Health |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2667118222000010 |
| _version_ | 1811298213376819200 |
|---|---|
| author | Stefania Chiappini Alessio Mosca Giovanni Martinotti Francesco Di Carlo Andrea Miuli Luigi Dattoli Mauro Pettorruso Massimo Di Giannantonio |
| author_facet | Stefania Chiappini Alessio Mosca Giovanni Martinotti Francesco Di Carlo Andrea Miuli Luigi Dattoli Mauro Pettorruso Massimo Di Giannantonio |
| author_sort | Stefania Chiappini |
| collection | DOAJ |
| description | Introduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g. palpitations, dizziness, diarrhoea, limb weakness, pain, and pseudo neurological symptoms) accompanied by one or more thoughts, feelings, and/or behaviours related to the somatic symptom(s) resulting in significant distress and/or dysfunction lasting for more than 6 months. At now the SSD can be refractory to psychiatric intervention including antidepressants, antiepileptics, and antipsychotics as well as the effectiveness of many of these treatments is limited. The objective of this study was to report the effectiveness of a third-generation antipsychotic drug brexpiprazole for treatment of a case of SSD together with the serotonin selective reuptake inhibitor (SSRI) fluvoxamine. Methods: A single case study of a 59-year-old female with SSD was here performed. Findings: After 4 weeks of treatment brexpiprazole, together with lamotrigine and fluvoxamine, was here effective in decreasing both depressive and anxiety symptoms, normalising previous unusual thought contents and of related behaviours. The patient reported an overall good response and started to function again in important domains of life. No adverse events occurred. Conclusion: To our knowledge, this is the first case showing Brexpiprazole effective for the treatment of a case of SSD as add-on to other drugs. |
| first_indexed | 2024-04-13T06:16:09Z |
| format | Article |
| id | doaj.art-5b9ac15eb849466d8d07fd8e71a2f535 |
| institution | Directory Open Access Journal |
| issn | 2667-1182 |
| language | English |
| last_indexed | 2024-04-13T06:16:09Z |
| publishDate | 2022-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Emerging Trends in Drugs, Addictions, and Health |
| spelling | doaj.art-5b9ac15eb849466d8d07fd8e71a2f5352022-12-22T02:58:49ZengElsevierEmerging Trends in Drugs, Addictions, and Health2667-11822022-01-012100031Brexpiprazole as a new approach of treatment in somatization disorderStefania Chiappini0Alessio Mosca1Giovanni Martinotti2Francesco Di Carlo3Andrea Miuli4Luigi Dattoli5Mauro Pettorruso6Massimo Di Giannantonio7Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, Italy; Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, Northern Ireland AL10 9AB, United Kingdom; Corresponding author.Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, ItalyDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, Italy; Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical Sciences, University of Hertfordshire, Hertfordshire, Northern Ireland AL10 9AB, United KingdomDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, ItalyDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, ItalyVilla Maria Pia, Via del Forte Trionfale 36, Roma 00135, ItalyDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, ItalyDepartment of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio, Chieti-Pescara, ItalyIntroduction: Somatic symptom disorder (SSD) is a mental disorder that involves one or more physical symptoms (e.g. palpitations, dizziness, diarrhoea, limb weakness, pain, and pseudo neurological symptoms) accompanied by one or more thoughts, feelings, and/or behaviours related to the somatic symptom(s) resulting in significant distress and/or dysfunction lasting for more than 6 months. At now the SSD can be refractory to psychiatric intervention including antidepressants, antiepileptics, and antipsychotics as well as the effectiveness of many of these treatments is limited. The objective of this study was to report the effectiveness of a third-generation antipsychotic drug brexpiprazole for treatment of a case of SSD together with the serotonin selective reuptake inhibitor (SSRI) fluvoxamine. Methods: A single case study of a 59-year-old female with SSD was here performed. Findings: After 4 weeks of treatment brexpiprazole, together with lamotrigine and fluvoxamine, was here effective in decreasing both depressive and anxiety symptoms, normalising previous unusual thought contents and of related behaviours. The patient reported an overall good response and started to function again in important domains of life. No adverse events occurred. Conclusion: To our knowledge, this is the first case showing Brexpiprazole effective for the treatment of a case of SSD as add-on to other drugs.http://www.sciencedirect.com/science/article/pii/S2667118222000010BrexpiprazoleSomatic symptom disorderThird-generation antipsychotic drug |
| spellingShingle | Stefania Chiappini Alessio Mosca Giovanni Martinotti Francesco Di Carlo Andrea Miuli Luigi Dattoli Mauro Pettorruso Massimo Di Giannantonio Brexpiprazole as a new approach of treatment in somatization disorder Emerging Trends in Drugs, Addictions, and Health Brexpiprazole Somatic symptom disorder Third-generation antipsychotic drug |
| title | Brexpiprazole as a new approach of treatment in somatization disorder |
| title_full | Brexpiprazole as a new approach of treatment in somatization disorder |
| title_fullStr | Brexpiprazole as a new approach of treatment in somatization disorder |
| title_full_unstemmed | Brexpiprazole as a new approach of treatment in somatization disorder |
| title_short | Brexpiprazole as a new approach of treatment in somatization disorder |
| title_sort | brexpiprazole as a new approach of treatment in somatization disorder |
| topic | Brexpiprazole Somatic symptom disorder Third-generation antipsychotic drug |
| url | http://www.sciencedirect.com/science/article/pii/S2667118222000010 |
| work_keys_str_mv | AT stefaniachiappini brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT alessiomosca brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT giovannimartinotti brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT francescodicarlo brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT andreamiuli brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT luigidattoli brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT mauropettorruso brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder AT massimodigiannantonio brexpiprazoleasanewapproachoftreatmentinsomatizationdisorder |